MacroGenics | MGNX - Ativo Circulante





Ativo Circulante Alterar Data
AbbVie USD 29.06B 523M 2025-12
Amgen USD 29.06B 1.17B 2025-12
AstraZeneca USD 29.61B 890M 2026-03
Biogen USD 9.19B 216.3M 2026-03
Bristol-Myers Squibb USD 35.63B 2.41B 2025-09
Daiichi Sankyo JPY 2.1T 218.5B 2025-12
Eli Lilly USD 55.63B 6.44B 2025-12
Genmab DKK 2.88B 1.59B 2025-12
Geron USD 520.27M 2.07M 2025-12
Gilead Sciences USD 19.89B 1.05B 2025-12
J&J USD 59.17B 3.55B 2026-03
Karyopharm Therapeutics USD 103.15M 13.4M 2025-12
MacroGenics USD 219.94M 12.15M 2025-12
Merck USD 47.56B 10.49B 2025-09
Pfizer USD 46.92B 3.22B 2025-09
Puma Biotechnology USD 143.58M 7M 2025-09
Regeneron Pharmaceuticals USD 18.21B 187.3M 2026-03
Roche Holding CHF 38.73B 3.03B 2025-12
Xencor USD 599.82M 81.38M 2025-12